Sugi Predict

Sugi Predict / Targets / RARG

RARG

Retinoic acid receptor gamma · P13631 · RARG on Sugi Atlas →

88,096 patent compounds predicted against RARG, 47,852 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL344900 SCHEMBL344900 1.00 19/20
SCHEMBL345684 SCHEMBL345684 1.00 19/20
SCHEMBL346037 SCHEMBL346037 1.00 19/20
SCHEMBL345356 SCHEMBL345356 0.79 19/20
SCHEMBL343651 SCHEMBL343651 0.78 19/20
SCHEMBL177444 SCHEMBL177444 1.00 18/20
SCHEMBL345071 SCHEMBL345071 1.00 18/20
SCHEMBL345553 SCHEMBL345553 0.76 18/20
SCHEMBL344736 SCHEMBL344736 0.60 18/20
SCHEMBL345649 SCHEMBL345649 0.58 18/20
SCHEMBL344714 SCHEMBL344714 0.71 15/20
SCHEMBL165750 SCHEMBL165750 1.00 14/20
SCHEMBL165751 SCHEMBL165751 1.00 14/20
SCHEMBL177719 SCHEMBL177719 0.73 14/20
SCHEMBL177720 SCHEMBL177720 0.73 14/20
SCHEMBL180433 SCHEMBL180433 0.64 14/20
Adapalene Adapalene (SCHEMBL2747) 1.00 13/20
O-Demethylated Adapalene O-Demethylated Adapalene (SCHEMBL174205) 1.00 13/20
Adapalene Adapalene (SCHEMBL297900) 0.96 13/20
SCHEMBL264372 SCHEMBL264372 0.55 13/20

Clinical trials — most relevant to RARG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia PHASE3UNKNOWN
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis PHASE2/PHASE3COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia PHASE2/PHASE3NOT_YET_RECRUITING
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia PHASE3COMPLETED
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation PHASE3COMPLETED
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. PHASE3UNKNOWN
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis PHASE2UNKNOWN
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. PHASE1/PHASE2UNKNOWN
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma PHASE1/PHASE2COMPLETED
Phase II 5-Azacytidine Plus VPA Plus ATRA PHASE2COMPLETED
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist) PHASE2COMPLETED
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) PHASE2COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
ATRA and Carfilzomib in Plasma Cell Myeloma Patients PHASE1/PHASE2RECRUITING
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma PHASE2RECRUITING
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow PHASE2COMPLETED
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors PHASE2RECRUITING
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid PHASE1UNKNOWN
Oral Clofarabine for Acute Myeloid Leukemia PHASE1COMPLETED
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML PHASE1COMPLETED
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients EARLY_PHASE1RECRUITING
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma EARLY_PHASE1COMPLETED
Prevalence Of Vitamin A Deficiency In Critically Ill Children With Sepsis And Its Association With Clinical Outcomes nanCOMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Vitamin A Supplementation in Preterm Infants nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RARG binder may also engage these)

ProteinNameSimilarity
P18911 — 1.000 P18911 →
P18514 — 0.998 P18514 →
Q9W5Z3 — 0.997 Q9W5Z3 →
P11416 — 0.996 P11416 →
RARA Retinoic acid receptor alpha 0.994 landscape →
Q7ZTI3 — 0.994 Q7ZTI3 →
Q5FBR4 — 0.992 Q5FBR4 →
P51126 — 0.992 P51126 →
P22605 — 0.992 P22605 →
P28699 — 0.992 P28699 →
Q9W6B3 — 0.992 Q9W6B3 →
RARB Retinoic acid receptor beta 0.991 landscape →
Q91392 — 0.991 Q91392 →
P22448 — 0.991 P22448 →
Q90271 — 0.991 Q90271 →
Q90966 — 0.990 Q90966 →
A2T928 — 0.986 A2T928 →
P18516 — 0.986 P18516 →
Q99MU3 — 0.976 Q99MU3 →
F1R7R1 — 0.972 F1R7R1 →
Q8K4S7 — 0.972 Q8K4S7 →
Q6NRE7 — 0.971 Q6NRE7 →
Q69ZT9 — 0.971 Q69ZT9 →
Q80U62 — 0.971 Q80U62 →
Q3TTA7 — 0.971 Q3TTA7 →
F1N2W9 — 0.970 F1N2W9 →
P55266 — 0.970 P55266 →
PI4KB Phosphatidylinositol 4-kinase beta 0.969 landscape →
O54828 — 0.969 O54828 →
Q80TJ7 — 0.969 Q80TJ7 →